New type of superior vaccines: Antigen entrapment in adjuvant alumina

Avnir David, HUJI, Faculty of Science, The Institute of Chemistry

Antigen and/or organic adjuvant entrapped within alumina adjuvant


Antibodies, Vaccinations, Drug delivery, Immunology, Adjuvants, Alumina

Development Stage

In vivo proof of concept

Patent Status

Provisional patent filed in the United States


The global market for human vaccines is forecast to reach $25 billion by 2015. Key factors driving market growth include replacement of existing products with second-generation products, introduction of new vaccines against diseases for which presently there exist no vaccines, and improving the storage and thermal stability of vaccines.

Our Innovation

Composite alumina entrapped vaccines – antigen or organic adjuvant or both entrapped within an alumina adjuvant.



  • Antigen-specific IgG titers exceeding 1:1,000,000 obtained in several mice using a single immunization (prime only) with low amount of antigen (7.2ugr x 1 vs. 25ugr x 3 in conventional adsorbed vaccines).
  • Antigen-specific IgG titers exceeding 1:256,000 obtained using extremely low antigen concentrations (2.5ugr, equivalent to 2 conventional immunizations using only 5% of the amount of antigen.
  • Long lasting immunological memory due to the sustained release
  • Significant gain in thermal stability.
  • Minimal number of doses: One dose
  • Additional expected benefits:
  • Reduced toxicity and side effects of the entrapped entity
  • Convenient administration: oral, nasal, pulmonary or topical
  • Stimulation of all arms of the specific immune system (B-cells, T-cells)
  • Synergetic effects


Figure shows extremely high antigen specific ovalbumin IgG titer observed 90 days following vaccination. This single immunization with the composite alumina entrapped vaccine produces results resembling those from three immunizations with conventional alumina vaccines demonstrating the ability to produce a safe, potent immune response and a long-lasting immunological memory to reduce the number of required immunizations.


We are currently looking for industrial cooperation

The Opportunity

“Acquired immune deficiency syndrome (AIDS), malaria and tuberculosis collectively cause more than five million deaths per year, but have nonetheless eluded conventional vaccine development and for this reason they represent one of the major global public health challenges as we enter the second decade of the twenty-first century.” Nature 473, 463–469 (26 May 2011) doi:10.1038/nature10124

Researcher Information         


Patent Status

Granted US 9,463,245

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: